Options
Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds
ISSN
1097-2765
Date Issued
2018
Author(s)
Agrawal, Anant A.
Cook, Andrew
Will, Cindy L.
Fekkes, Peter
Smith, Peter G.
Larsen, Nicholas
Buonamici, Silvia
Pena, Vladimir
DOI
10.1016/j.molcel.2018.03.011
Abstract
SF3B is a multi-protein complex essential for branch site (BS) recognition and selection during pre-mRNA splicing. Several splicing modulators with antitumor activity bind SF3B and thereby modulate splicing. Here we report the crystal structure of a human SF3B core in complex with pladienolide B (PB), a macrocyclic splicing modulator and potent inhibitor of tumor cell proliferation. PB stalls SF3B in an open conformation by acting like a wedge within a hinge, modulating SF3B's transition to the closed conformation needed to form the BS adenosine-binding pocket and stably accommodate the BS/U2 duplex. This work explains the structural basis for the splicing modulation activity of PB and related compounds, and reveals key interactions between SF3B and a common pharmacophore, providing a framework for future structure-based drug design.